20 completed, 20 recruiting, 4 active not recruiting, 4 terminated. 20 Phase 2, 9 Phase 3, 7 Early Phase 1, 7 Phase 1, 6 Phase 4.
Follow Blue Earth Diagnostics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG 18F-Fluciclovine - Glioma, Low-grade Glioma | Early Phase 1 | Recruiting | Children's Hospital of Philadelphia | 30 | 2026-11-29 | 2026-09-22 |
| Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence fluciclovine (18F) - Prostate Cancer | Phase 4 | Recruiting | Blue Earth Diagnostics | 142 | 2026-08-31 | 2026-10-07 |
| Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer Posluma PET - Prostate Cancer | Phase 2 | Not yet recruiting | Aditya Bagrodia | 22 | 2026-08-01 | 2026-08-14 |
| Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT Leuprolide, Degarelix, Relugolix - Prostate Cancer, Localized Prostate Carcinoma | Phase 2 | Recruiting | Baptist Health South Florida | 50 | 2026-07-29 | 2026-08-06 |
| [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications [68Ga]BED003 - Colorectal Cancer, Epithelial Ovarian Cancer | Phase 2 | Recruiting | Blue Earth Diagnostics | 71 | 2026-06-30 | 2026-09-15 |
| Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation Flotufolastat F18 PET - Prostate Adenocarcinoma, Prostate Cancer | Phase 2 | Not yet recruiting | University of California, Irvine | 60 | 2026-05-01 | 2026-05-06 |
| Androgen-responsive POSLUMA-guided Intra-prostatic Boost PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost - Intermediate Risk Prostate Cancer, High Risk Prostate Cancer | Phase 2 | Recruiting | Martin T. King, MD, PhD | 23 | 2026-04-29 | 2026-05-29 |
| [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications [18F]FPyQCP - Colorectal Cancer, Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Blue Earth Diagnostics | 71 | 2026-02-19 | 2026-10-28 |
| Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18 - Prostatic Neoplasms, Prostate Cancer | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 120 | 2026-02-10 | 2026-02-23 |
| Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial Biopsy of Prostate, Biospecimen Collection, Computed Tomography - Prostate Carcinoma | Early Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-11-14 | 2026-03-10 |
| An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer. Computed Tomography, Fluorine F 18 Flotufolastat, Positron Emission Tomography - Prostate Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 81 | 2025-10-09 | 2026-09-29 |
| Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment 18F-rhPSMA-7.3 - Prostate Cancer | Not applicable | Recruiting | Hackensack Meridian Health | 70 | 2025-10-01 | 2026-03-23 |
| Flotufolastat F 18 PET in Men With Very Low PSA Recurrence Positron Emission Tomography (PET) - Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen | Recruiting | Massachusetts General Hospital | 50 | 2025-05-20 | 2026-05-15 | |
| Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy flotufolastat (18F), piflufolastat (18F) - Prostate Cancer | Phase 4 | Completed | Blue Earth Diagnostics | 62 | 2024-12-04 | 2026-07-13 |
| A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy 18F-Fluciclovine (Axumin), Pet Scan - Brain Metastases | Not applicable | Terminated | M.D. Anderson Cancer Center | 3 | 2024-11-07 | 2026-09-23 |
| PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence 18F-rhPSMA-7.3 (Posluma) - Prostate Cancer (Post Prostatectomy) | Phase 2 | Recruiting | AdventHealth | 30 | 2024-09-20 | 2024-10-24 |
| Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis 18F-Fluciclovine (Axumin) PET/CT - Brain Metastases | Early Phase 1 | Recruiting | University of Arizona | 20 | 2024-09-10 | 2026-09-21 |
| 18F-Fluciclovine PET-MRI in High-grade Glioma 18F-Fluciclovine PET-MRI - Glioma, High Grade Glioma | Early Phase 1 | Recruiting | Children's Hospital of Philadelphia | 30 | 2024-08-07 | 2025-12-04 |
| PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer 18F-rhPSMA-7.3, PET/CT - Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer | Phase 4 | Active not recruiting | Brigham and Women's Hospital | 20 | 2024-06-30 | 2026-10-29 |
| Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging flotufolastat F 18, Relugolix 120 MG, Serum PSA and Testosterone - Prostate Cancer | Early Phase 1 | Completed | Urology Clinics of North Texas | 10 | 2024-06-15 | 2025-07-16 |
Showing 20 of 55. Sign in to see all of them.
Prostatic Neoplasms (28) · Brain Neoplasms (11) · Disease (4) · Carcinoma, Ovarian Epithelial (3) · Glioma (3) · Carcinoma, Lobular (2) · Colorectal Neoplasms (2) · Stomach Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Glioblastoma (1) · Lymphoma, Follicular (1)
fluciclovine F-18 (24) · Magnetic Resonance Spectroscopy (7) · Positron Emission Tomography Computed Tomography (5) · Positron-Emission Tomography (4) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (3) · Injections (3) · X-Rays (2) · bicalutamide (2) · relugolix (2) · Abiraterone Acetate (1) · Androgen Antagonists (1) · Furosemide (1) · Glutamate Carboxypeptidase II (1) · Leuprolide (1) · Lymph Node Excision (1)
United States (49) · Finland (4) · Netherlands (3) · Italy (2) · United Kingdom (2) · Germany (1) · Norway (1)
Heather Jacene, MD (3) · Mariam Aboian, MD,PhD (2) · Wayne Brisbane (2) · Aditya Bagrodia, MD, FACS (1) · Adrian Harris, Prof (1) · Ashutosh Tewari (1) · Bital Savir-Baruch, M.D (1) · Bital Savir-Baruch, MD (1) · Brian Helfand, M.D. (1) · Brian Lewis, MD, MPH, FACP (1) · Charles V. Marcus, MBBS (1) · Daniel M. Trifiletti, MD (1) · David Schuster, MD (1) · Eugene Teoh, MD (1) · Evan Yu (1)
PMID 34081125, PMID 31216198, PMID 37121865, PMID 27746282, PMID 29147764, PMID 31624865, PMID 32068113, PMID 33846844, PMID 34795409, PMID 37414702, PMID 38782456, PMID 39848765, PMID 41729277, PMID 42850466
2025 (1), P30CA138292 (1)